Compare Abeona Therapeutics Inc (ABEO) vs Hershey Co (HSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hershey Co — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Hershey Co trades at $176.07 (market cap $35.69B). The key difference: Hershey Co is far larger — about 95.6× Abeona Therapeutics Inc's market cap, and Hershey Co pays a 3.3% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HSY | |
|---|---|---|
Market Cap | $373.32M | $35.69B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $236.28 |
52-Week Low | $4.17 | $161.95 |
Enterprise Value | $228.22M | $40.49B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Hershey (HSY) trades at $175.95, down 3.4% over the past day, with a bearish technical signal but strong recent earnings beats. The stock shows a high P/E ratio of 33.06 and a net income margin of 9.12%, supported by consistent cash flow from operations of $2.28B in 2025. Recent corporate actions include a $1.45 dividend and executive appointments, while cocoa cost pressures show signs of easing according to MarketBeat (July 1, 2026).
The outlook is mixed: analyst consensus targets $211.27 with 65.72% hold ratings, indicating cautious optimism amid valuation concerns. Key risks include commodity inflation and competitive pressures, but margin recovery and dividend yield near 3.2% offer potential for income-focused investors. Upside depends on sustained earnings growth and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
